论文部分内容阅读
目的观察超选择性脑动脉灌注替尼泊甙（ＶＭ２６）并卡氮芥（ＢＣＮＵ）静滴治疗恶性脑瘤的临床疗效。方法对４７例脑瘤于手术切除后，采用超选择性脑动脉灌注ＶＭ２６并ＢＣＮＵ静滴，于化疗后６个月分别用ＣＴ检查肿瘤体积变化及评价临床症状，并与化疗前比较。结果本组化疗前肿瘤平均体积为（１６．１５±６．８８）ｃｍ３，化疗后平均体积为（８．８９±１１．４２）ｃｍ３（Ｐ＜０．０１），总有效率为７２３％（３４／４７）（完全缓解率为２１．３％），稳定不变１０．６％（５／４７），恶化占１２．７％（６／４７）。本组病例１年存活率达８５．１％（４０／４７），２年存活率为７０．２％（３３／４７），全部患者均无眼部症状及严重的神经副反应。结论认为超选择性脑动脉联合化疗的方法，存活率较单纯颈内动脉灌注化疗及外周静脉化疗高，而且并发症少，全身反应轻。
Objective To observe the clinical effect of super selective cerebral artery infusion of tenimoside (VM26) combined with intravenous infusion of BCNU on malignant brain tumors. Methods 47 cases of brain tumor after surgical resection, the use of ultra-selective intracerebral perfusion of VM26 and BCNU intravenous infusion, 6 months after chemotherapy with CT examination of tumor volume changes and evaluation of clinical symptoms, and compared with before chemotherapy. Results The average volume of tumor before chemotherapy in this group was (16.15 ± 6.88) cm3, and the average volume after chemotherapy was (8.89 ± 11.42) cm3 (P <0.01). The total effective rate was 723 % (34/47) (complete response rate was 21.3%), unchanged at 10.6% (5/47) and worsened at 12.7% (6/47). The 1-year survival rate was 85.1% (40/47) and the 2-year survival rate was 70.2% (33/47). All patients had no ocular symptoms and severe neurological side effects. Conclusion Superselective cerebral artery chemotherapy combined with chemotherapy, survival rate than simple intra-arterial infusion chemotherapy and peripheral vein chemotherapy, and less complications, less systemic reactions.